TY - JOUR
T1 - Rebamipide and Derivatives are Potent, Selective Inhibitors of Histidine Phosphatase Activity of the Suppressor of T Cell Receptor Signaling Proteins
AU - Aziz, Faisal
AU - Reddy, Kanamata
AU - Fernandez Vega, Virneliz
AU - Dey, Raja
AU - Hicks, Katherine A.
AU - Rao, Sumitha
AU - Jordan, Luis Ortiz
AU - Smith, Emery
AU - Shumate, Justin
AU - Scampavia, Louis
AU - Carpino, Nicholas
AU - Spicer, Timothy P.
AU - French, Jarrod B.
N1 - Publisher Copyright:
© 2024 American Chemical Society.
PY - 2024/2/8
Y1 - 2024/2/8
N2 - The suppressor of T cell receptor signaling (Sts) proteins are negative regulators of immune signaling. Genetic inactivation of these proteins leads to significant resistance to infection. From a 590,000 compound high-throughput screen, we identified the 2-(1H)-quinolinone derivative, rebamipide, as a putative inhibitor of Sts phosphatase activity. Rebamipide, and a small library of derivatives, are competitive, selective inhibitors of Sts-1 with IC50 values from low to submicromolar. SAR analysis indicates that the quinolinone, the acid, and the amide moieties are all essential for activity. A crystal structure confirmed the SAR and reveals key interactions between this class of compound and the protein. Although rebamipide has poor cell permeability, we demonstrated that a liposomal preparation can inactivate the phosphatase activity of Sts-1 in cells. These studies demonstrate that Sts-1 enzyme activity can be pharmacologically inactivated and provide foundational tools and insights for the development of immune-enhancing therapies that target the Sts proteins.
AB - The suppressor of T cell receptor signaling (Sts) proteins are negative regulators of immune signaling. Genetic inactivation of these proteins leads to significant resistance to infection. From a 590,000 compound high-throughput screen, we identified the 2-(1H)-quinolinone derivative, rebamipide, as a putative inhibitor of Sts phosphatase activity. Rebamipide, and a small library of derivatives, are competitive, selective inhibitors of Sts-1 with IC50 values from low to submicromolar. SAR analysis indicates that the quinolinone, the acid, and the amide moieties are all essential for activity. A crystal structure confirmed the SAR and reveals key interactions between this class of compound and the protein. Although rebamipide has poor cell permeability, we demonstrated that a liposomal preparation can inactivate the phosphatase activity of Sts-1 in cells. These studies demonstrate that Sts-1 enzyme activity can be pharmacologically inactivated and provide foundational tools and insights for the development of immune-enhancing therapies that target the Sts proteins.
UR - http://www.scopus.com/inward/record.url?scp=85184668588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184668588&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.3c01763
DO - 10.1021/acs.jmedchem.3c01763
M3 - Article
C2 - 38252624
AN - SCOPUS:85184668588
SN - 0022-2623
VL - 67
SP - 1949
EP - 1960
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 3
ER -